[1] Shoraka S, Mohebbi SR, Hosseini SM,et al. Identification of plasma lncRNA-ATB levels in hepatitis B virus-related cirrhosis and non-cirrhotic chronic hepatitis B patients. J Virus Res, 2021, 303:198503. [2] Meng X, Pan Z, Zhao J,et al. Efficacy and safety of Fufang Biejia Ruangan Tablets as an adjuvant treatment for chronic hepatitis B liver fibrosis: A systematic review and meta-analysis J. Medicine (Baltimore), 2022, 101(46):e31664. [3] 冯志刚,李涛,赵冰清,等.复方鳖甲软肝片联合恩替卡韦对乙肝肝硬化失代偿期患者疗效、肝功能、免疫功能影响研究.中华中医药学刊,2022,40(1):184-187. [4] Chen CH, Jeng WJ, Hu TH,et al. HBV relapse rates in patients who discontinue tenofovir disoproxil fumarate with or without switching totenofovir alafenamide J. Dig Liver Dis, 2023, 55(6):771-777. [5] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2022年版).实用肝脏病杂志,2023,26(3)S18-39. [6] Jung CY, Jung HY, Kim HW,et al. Fibrotic burden in patients with hepatitis B virus-related cirrhosis is independently associated with poorer kidney outcomes J. J Infect Dis, 2024, 229(1):108-116. [7] Tu A, Zhu X, Dastjerdi PZ, et al. Evaluate the clinical efficacy of traditional Chinesemedicine as the neoadjuvant treatment in reducing the incidence of hepatocellular carcinoma in patients with hepatitis B-related cirrhosis: A systematic review and meta-analysis J. Heliyon, 2024, 10(3):e24437. [8] He J, Guo Y, Zhang Y,et al. Comparison of pegylated interferon alfa therapy in combination with tenofovir alafenamide fumarate or tenofovir disoproxil fumarate for treatment of chronic hepatitis B patients J. Infect Drug Resist, 2023, 16:3929-3941. [9] 欧阳冰琛,赵权,王晶,等.LC-MS/MS法同时测定复方鳖甲软肝片中9种成分.中成药,2022,44(12):3787-3791. [10] Schafer JJ, Zimmerman M, Walshe C,et al. Weight changes in patients with sustained viral suppression switching tenofovir disoproxil fumarate to tenofovir alafenamide J. Obesity (Silver Spring), 2022, 30(6):1197-1204. [11] Sevenler D, Niu X, Dossantos S, et al. Point-of-care semi-quantitative test for adherence to tenofovir alafenamide or tenofovir disoproxil fumarate J. J Antimicrob Chemother, 2022, 77(4):996-999. [12] Tian X, Dong H, Lai X,et al. TRIM56 impairs HBV infection and replication by inhibiting HBV core promoter activity J. Antiviral Res, 2022, 207:105406. [13] Li B, Liu Z, Liu X, et al. Efficacy and safety of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in preventing HBV vertical transmission of high maternal viral load J. Hepatol Int, 2021, 15(5):1103-1108. [14] Akbar SMF, Al Mahtab M, Khan S,et al. Innovative therapies targeting the virus and the host for treating chronic hepatitis B virus infection: from bench to bedside J. Vaccines (Basel), 2022, 10(5):746. [15] Wang P, Yang Y, Pang G,et al. Hepatocyte-derived MANF is protective for rifampicin-induced cholestatic hepatic injury via inhibiting ATF4-CHOP signal activation J. Free Radic Biol Med, 2021, 162:283-297. [16] Buchl SC, Hanquier Z, Haak AJ,et al. Traf2 and NCK interacting kinase is a critical regulator of procollagen I trafficking and hepatic fibrogenesis in mice. J Hepatol Commun, 2022, 6(3):593-609. [17] 熊雪丽,张江春,胡乃毅,等.实时二维剪切波弹性成像对乙型肝炎肝硬化门静脉高压患者曲张静脉出血风险的预测价值分析.中国现代医学杂志,2023,33(1):76-81. [18] Lin LY, Zeng DW, Liu YR,et al. Diagnostic value of liver stiffness measurement combined with risk scores for esophagogastric variceal bleeding in patients with hepatitis B cirrhosis. JEur J Radiol, 2024, 173:111385. [19] Vukotic R, Di Donato R, Roncarati G,et al. 5-MTHF enhances the portal pressure reduction achieved with propranolol in patients withcirrhosis: A randomized placebo-controlled trial. J Hepatol, 2023, 79(4):977-988. [20] Van Welzen BJ, Thielen MAJ, Mudrikova T,et al. Switching tenofovir disoproxil fumarate to tenofovir alafenamide results in a significant decline in parathyroid hormone levels: uncovering the mechanism of tenofovir disoproxil fumarate-related bone loss? J AIDS, 2019, 33(9):1531-1534. |